GT Biopharma, Inc. (GTBP), a clinical-stage immuno-oncology company, has announced the advancement of its ongoing Phase 1 dose-escalation trial of GTB-3650 to Cohort 2 following the successful completion of dosing in the first patient group, i.e., Cohort 1.
The trial is evaluating GTB-3650, a second-generation TriKE or Tri-specific Killer Engager immunotherapy, for the treatment of relapsed or refractory or r/r CD33-expressing hematologic malignancies.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.